520 reports of this reaction
3.9% of all BINIMETINIB reports
#6 most reported adverse reaction
PRODUCT USE IN UNAPPROVED INDICATION is the #6 most commonly reported adverse reaction for BINIMETINIB, manufactured by Array BioPharma Inc.. There are 520 FDA adverse event reports linking BINIMETINIB to PRODUCT USE IN UNAPPROVED INDICATION. This represents approximately 3.9% of all 13,446 adverse event reports for this drug.
Patients taking BINIMETINIB who experience product use in unapproved indication should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PRODUCT USE IN UNAPPROVED INDICATION is moderately reported among BINIMETINIB users, representing a notable but not dominant share of adverse events.
In addition to product use in unapproved indication, the following adverse reactions have been reported for BINIMETINIB:
The following drugs have also been linked to product use in unapproved indication in FDA adverse event reports:
PRODUCT USE IN UNAPPROVED INDICATION has been reported as an adverse event in 520 FDA reports for BINIMETINIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
PRODUCT USE IN UNAPPROVED INDICATION accounts for approximately 3.9% of all adverse event reports for BINIMETINIB, making it a notable side effect.
If you experience product use in unapproved indication while taking BINIMETINIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.